A resolution relating to price disclosures of prescription drugs.

Declares that restraints on accurate prescription drug price disclosure are contrary to the public interest and that there is a need for a system of adequate price disclosure of prescription drugs.

Expresses the sense of the Senate that the following practices are unfair trade practices within the meaning of the Federal Trade Commission Act: (1) restrictions on the disclosure by any retail seller of accurate price information regarding prescription drugs; (2) the failure of any retail seller to disclose adequate retail price information when requested of him; and (3) restrictions on the disclosure of adequate price information by any means of public communication.